What does working in a lab have in common with flying an airplane? A great deal according to the next researcher highlighted in our “I am Research, Progress, Hope” series, Dowdy Jackson, head of the Antibody Drug Conjugate (ADC) Biology group at Agensys, an affiliate of Astellas.
Most Recent Posts
As of January 1, researchers are now able to submit proposals to receive access to patient level data, protocols, and clinical study reports for new medicines approved in the U.S and EU after January 1, 2014. The biopharmaceutical sector’s commitment to data sharing provides new avenues for the scientific community and patients to benefit from clinical research, while maintaining patient privacy, the integrity of national regulators, and incentives for companies to make long-term investments in biomedical research.
Dr. Robert Freeman, Professor of Pharmacy Administration (health services research) in the Department of Pharmacy Practice & Administration at the University of Maryland Eastern Shore School of Pharmacy, comments on the recently released paper from University College London School of Pharmacy on patient’s needs and intellectual property in middle income countries.
In his State of the Union, President Obama said, "A nation that goes all-in on innovation today will own the global economy tomorrow." We couldn't agree more.
Today’s featured scientist comes from Agensys, a subsidiary of Astellas, where she is working on developing a treatment or cure for different types of cancers.
The great inventor and businessman Henry Ford once said, “Whether you think you can, or think you can’t – you’re right."
When looking at an issue as important and complex as health care costs in the U.S., it’s critical that full facts, not select data, lead the discussion. Drew Armstrong’s recent article about a Hepatitis C medicine paints an incomplete picture of our health care system and further propels inaccurate information about prescription medicines.
When considering the benefits and risks of medicines, patients provide a unique perspective of unparalleled value. A deep understanding of the patient perspective on benefits and risks throughout the drug development process has the potential to significantly advance the biopharmaceutical industry’s efforts to bring to patients new medicines that extend and improve the quality of their lives.
Before the holidays, PhRMA’s General Counsel Mit Spears wrote a post in The Catalyst about the need for a new regulatory paradigm to govern how the biopharmaceutical industry communicates with healthcare professionals about the medicines that our companies research and develop.
Dr. Richard Moscicki, Deputy Center Director for Science Operations at the Center for Drug Evaluation and Research at the Food and Drug Administration (FDA), noted in his remarks at the FDA public workshop on Complex Issues in Developing Drug and Biological Products for Rare Diseases held earlier this month that more than a third of the novel drugs approved in CY13 treat rare disease.
Nelson Mandela once said, “Education is the most powerful weapon which you can use to change the world.” This statement couldn't be more accurate.
This week at the STEM Saves Lives forum, we were fortunate enough to hear from the first woman of color to go into space. Now, we hear from a woman who considered taking a similar path, but instead decided to pursue a career in biopharmaceutical research.
It’s been widely reported that the United States has a science, technology, engineering and math (STEM) education problem. As we fall behind other countries in STEM proficiencies, our leadership in innovation across sectors is at risk.
The next new addition to our “I am Research, Progress, Hope” series is a scientist from Pfizer who works in neuroscience – leading a multi-disciplinary team focusing on Alzheimer’s and other serious diseases of the brain including schizophrenia.
Like a complex puzzle, the research and development (R&D) process for new medicines requires many pieces to work concurrently to ensure success. From the patients who inspire us to the experts behind the research, every part is critical to a prosperous pipeline for patients suffering from some of the world’s most debilitating diseases.